NCT05342584View on ClinicalTrials.gov

Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS

PHASE1RecruitingINTERVENTIONAL

Enrollment

99

Participants

Timeline

Start Date

May 25, 2022

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions

Acute Myeloid LeukemiaMyelodysplastic Syndromes

Interventions

DRUG

Venetoclax Oral Tablet

Given PO

DRUG

Daunorubicin

Given IV

DRUG

Cytarabine

Given IV

Trial Locations (1)

10467

RECRUITING

Montefiore Einstein Cancer Center, The Bronx

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

AbbVie

INDUSTRY

lead

Ioannis Mantzaris

OTHER